Share Price and Basic Stock Data
Last Updated: December 11, 2025, 9:54 pm
| PEG Ratio | -1.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Trigyn Technologies Ltd operates in the IT consulting and software sector, where it has faced a fluctuating revenue landscape in recent quarters. For the financial year ending March 2025, the company’s total sales stood at ₹898 Cr, a notable decline from ₹1,280 Cr the previous year. The revenue trend shows a peak in FY 2023, with sales hitting ₹1,273 Cr before tapering off sharply. In Q1 FY 2025, sales were recorded at ₹334.14 Cr, which is a decline from ₹306.90 Cr in Q4 FY 2024. The company has demonstrated a capacity for growth in the past, but the recent sales drop raises concerns about sustaining momentum in a competitive market. The operating profit margin (OPM) has been under pressure, with a reported -1.07% for the latest quarter, indicating potential inefficiencies and high costs relative to revenue. As Trigyn navigates these challenges, the focus will be on reversing this downward trend and identifying new growth opportunities to stabilize its revenue base.
Profitability and Efficiency Metrics
When examining profitability, Trigyn’s figures depict a challenging scenario. The company reported a net profit of just ₹12 Cr for FY 2025, down from ₹20 Cr the previous year. The net profit margin also reflects this decline, standing at a mere 1.31%, significantly lower compared to industry peers, who often range between 10-15%. Furthermore, the return on equity (ROE) is quite modest at 1.72%, suggesting that shareholders may not be receiving adequate returns on their investments. Efficiency metrics reveal a cash conversion cycle of 99 days, which seems stretched compared to industry standards, where shorter cycles are preferred. This inefficiency could tie up capital that might otherwise be invested in growth initiatives. The interest coverage ratio is strong at 12.76x, indicating that the company can comfortably meet its interest obligations, but the overall profitability picture remains concerning.
Balance Sheet Strength and Financial Ratios
Trigyn’s balance sheet shows a somewhat stable structure, with total assets amounting to ₹903 Cr and total liabilities at ₹903 Cr as of March 2025. The company’s reserves have grown to ₹731 Cr, providing a cushion against operational volatility. However, the low debt levels, with borrowings at ₹7 Cr, position Trigyn as a low-leverage entity, which can be a double-edged sword. While this indicates financial prudence, it also raises questions about whether the company is leveraging opportunities for growth. The price-to-book value ratio stands at a low 0.28x, signaling that the stock may be undervalued relative to its net assets. However, the stark decline in profitability and revenue growth poses risks that may overshadow these seemingly positive financial metrics. Investors should consider whether the current asset base and financial ratios can translate into future growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Trigyn Technologies reveals a strong promoter holding of 44.51%, which can instill confidence among retail investors. However, foreign institutional investors (FIIs) and domestic institutional investors (DIIs) have minimal presence, at 0.14% and 0.01% respectively, indicating a lack of institutional faith in the company’s growth prospects. The public holding stands at 55.35%, which points to a broad base of retail investors but also highlights potential volatility due to sentiment swings. The number of shareholders has slightly decreased from 38,413 in December 2022 to 34,157 in September 2025, suggesting that some investors are losing confidence in the stock. This trend could impact liquidity and the stock’s ability to recover if performance does not improve. Building investor confidence through transparent communication and strategic initiatives will be vital for Trigyn moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Trigyn Technologies faces a mixed outlook. The company’s low debt levels and substantial reserves provide a safety net, but its declining revenue and profitability metrics are concerning. Investors might be cautious given the volatile nature of the IT consulting sector, especially as margins tighten and competition intensifies. Additionally, the lack of institutional support could exacerbate stock price volatility. On the other hand, if Trigyn can successfully pivot its business strategy to focus on high-margin projects and improve operational efficiencies, there is potential for recovery. The key risks include further declines in revenue, inability to manage expenses, and the challenge of attracting institutional investors. Ultimately, investors should weigh these factors carefully, considering both the inherent strengths and vulnerabilities of Trigyn Technologies as they navigate their investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Trigyn Technologies Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Visesh Infotecnics Ltd | 125 Cr. | 0.33 | / | 1.11 | 0.00 % | 2.21 % | 2.23 % | 1.00 | |
| Mudunuru Ltd | 48.2 Cr. | 15.3 | 15.3/4.43 | 0.20 | 0.00 % | 27.0 % | 90.7 % | 2.00 | |
| Naapbooks Ltd | 139 Cr. | 129 | 194/99.8 | 21.2 | 36.4 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 24.3 Cr. | 190 | 310/140 | 17.4 | 26.7 | 0.53 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 5.52 Cr. | 1.13 | 1.73/0.91 | 2.47 | 0.00 % | 2.14 % | 2.15 % | 2.00 | |
| Industry Average | 20,431.97 Cr | 554.59 | 86.80 | 123.78 | 0.55% | 14.89% | 20.93% | 6.84 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 285.27 | 323.64 | 339.78 | 324.04 | 322.50 | 316.12 | 306.90 | 334.14 | 241.94 | 207.81 | 206.78 | 239.66 | 224.50 |
| Expenses | 272.16 | 306.53 | 317.16 | 316.07 | 304.80 | 299.96 | 323.41 | 316.78 | 232.47 | 203.92 | 207.41 | 234.15 | 226.91 |
| Operating Profit | 13.11 | 17.11 | 22.62 | 7.97 | 17.70 | 16.16 | -16.51 | 17.36 | 9.47 | 3.89 | -0.63 | 5.51 | -2.41 |
| OPM % | 4.60% | 5.29% | 6.66% | 2.46% | 5.49% | 5.11% | -5.38% | 5.20% | 3.91% | 1.87% | -0.30% | 2.30% | -1.07% |
| Other Income | 0.51 | 1.27 | 2.47 | 2.23 | 3.21 | 3.10 | 2.42 | 3.26 | 4.00 | 3.65 | 4.40 | 3.96 | 4.28 |
| Interest | 0.70 | 0.53 | 0.54 | 0.47 | 0.42 | 0.38 | 0.33 | 0.53 | 0.33 | 0.27 | 0.29 | 1.88 | 0.54 |
| Depreciation | 1.65 | 1.67 | 1.70 | 1.78 | 1.67 | 1.58 | 1.55 | 2.07 | 1.27 | 1.47 | 1.03 | 1.24 | 0.78 |
| Profit before tax | 11.27 | 16.18 | 22.85 | 7.95 | 18.82 | 17.30 | -15.97 | 18.02 | 11.87 | 5.80 | 2.45 | 6.35 | 0.55 |
| Tax % | 47.20% | 33.19% | 32.87% | 67.42% | 35.76% | 37.17% | 37.88% | -5.33% | 35.89% | 93.79% | 49.80% | 59.69% | 940.00% |
| Net Profit | 5.94 | 10.81 | 15.34 | 2.59 | 12.09 | 10.86 | -22.02 | 18.98 | 7.61 | 0.36 | 1.23 | 2.56 | -4.61 |
| EPS in Rs | 1.93 | 3.51 | 4.98 | 0.84 | 3.93 | 3.53 | -7.15 | 6.17 | 2.47 | 0.12 | 0.40 | 0.83 | -1.50 |
Last Updated: August 20, 2025, 2:00 am
Below is a detailed analysis of the quarterly data for Trigyn Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 224.50 Cr.. The value appears to be declining and may need further review. It has decreased from 239.66 Cr. (Mar 2025) to 224.50 Cr., marking a decrease of 15.16 Cr..
- For Expenses, as of Jun 2025, the value is 226.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 234.15 Cr. (Mar 2025) to 226.91 Cr., marking a decrease of 7.24 Cr..
- For Operating Profit, as of Jun 2025, the value is -2.41 Cr.. The value appears to be declining and may need further review. It has decreased from 5.51 Cr. (Mar 2025) to -2.41 Cr., marking a decrease of 7.92 Cr..
- For OPM %, as of Jun 2025, the value is -1.07%. The value appears to be declining and may need further review. It has decreased from 2.30% (Mar 2025) to -1.07%, marking a decrease of 3.37%.
- For Other Income, as of Jun 2025, the value is 4.28 Cr.. The value appears strong and on an upward trend. It has increased from 3.96 Cr. (Mar 2025) to 4.28 Cr., marking an increase of 0.32 Cr..
- For Interest, as of Jun 2025, the value is 0.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.88 Cr. (Mar 2025) to 0.54 Cr., marking a decrease of 1.34 Cr..
- For Depreciation, as of Jun 2025, the value is 0.78 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.24 Cr. (Mar 2025) to 0.78 Cr., marking a decrease of 0.46 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.55 Cr.. The value appears to be declining and may need further review. It has decreased from 6.35 Cr. (Mar 2025) to 0.55 Cr., marking a decrease of 5.80 Cr..
- For Tax %, as of Jun 2025, the value is 940.00%. The value appears to be increasing, which may not be favorable. It has increased from 59.69% (Mar 2025) to 940.00%, marking an increase of 880.31%.
- For Net Profit, as of Jun 2025, the value is -4.61 Cr.. The value appears to be declining and may need further review. It has decreased from 2.56 Cr. (Mar 2025) to -4.61 Cr., marking a decrease of 7.17 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.50. The value appears to be declining and may need further review. It has decreased from 0.83 (Mar 2025) to -1.50, marking a decrease of 2.33.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:14 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 451 | 492 | 625 | 679 | 685 | 895 | 911 | 985 | 1,041 | 1,273 | 1,280 | 898 | 879 |
| Expenses | 407 | 456 | 563 | 612 | 623 | 810 | 833 | 893 | 975 | 1,212 | 1,245 | 880 | 872 |
| Operating Profit | 44 | 36 | 62 | 67 | 61 | 85 | 77 | 92 | 65 | 61 | 35 | 18 | 6 |
| OPM % | 10% | 7% | 10% | 10% | 9% | 9% | 8% | 9% | 6% | 5% | 3% | 2% | 1% |
| Other Income | 56 | 5 | 2 | 1 | 1 | -4 | 5 | 3 | 3 | 6 | 12 | 17 | 16 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 7 | 7 | 7 | 5 | 5 |
| Profit before tax | 98 | 40 | 62 | 66 | 60 | 78 | 78 | 89 | 59 | 58 | 38 | 26 | 15 |
| Tax % | 18% | 39% | 38% | 41% | 34% | 38% | 36% | 30% | 34% | 40% | 48% | 56% | |
| Net Profit | 81 | 24 | 38 | 39 | 39 | 48 | 50 | 62 | 39 | 35 | 20 | 12 | -0 |
| EPS in Rs | 27.49 | 8.32 | 13.02 | 13.13 | 13.20 | 15.74 | 16.27 | 20.19 | 12.69 | 11.26 | 6.48 | 3.82 | -0.15 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 2% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -70.37% | 58.33% | 2.63% | 0.00% | 23.08% | 4.17% | 24.00% | -37.10% | -10.26% | -42.86% | -40.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 128.70% | -55.70% | -2.63% | 23.08% | -18.91% | 19.83% | -61.10% | 26.84% | -32.60% | 2.86% |
Trigyn Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -23% |
| 3 Years: | -30% |
| TTM: | -99% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | -10% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 4, 2025, 2:08 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 29 | 29 | 30 | 30 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 193 | 218 | 260 | 297 | 341 | 403 | 473 | 527 | 577 | 650 | 670 | 710 | 731 |
| Borrowings | 0 | 0 | 0 | 0 | 1 | 8 | 6 | 10 | 7 | 7 | 5 | 13 | 7 |
| Other Liabilities | 49 | 51 | 57 | 58 | 75 | 100 | 108 | 115 | 140 | 168 | 168 | 150 | 148 |
| Total Liabilities | 271 | 299 | 347 | 385 | 446 | 541 | 618 | 683 | 755 | 856 | 874 | 903 | 916 |
| Fixed Assets | 92 | 91 | 88 | 89 | 90 | 90 | 100 | 99 | 108 | 107 | 103 | 97 | 96 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 0 | 0 |
| Investments | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 5 | 21 | 83 | 17 | 38 | 33 |
| Other Assets | 179 | 207 | 258 | 295 | 355 | 447 | 513 | 577 | 624 | 665 | 755 | 769 | 788 |
| Total Assets | 271 | 299 | 347 | 385 | 446 | 541 | 618 | 683 | 755 | 856 | 874 | 903 | 916 |
Below is a detailed analysis of the balance sheet data for Trigyn Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
- For Reserves, as of Sep 2025, the value is 731.00 Cr.. The value appears strong and on an upward trend. It has increased from 710.00 Cr. (Mar 2025) to 731.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 6.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 148.00 Cr.. The value appears to be improving (decreasing). It has decreased from 150.00 Cr. (Mar 2025) to 148.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 916.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 903.00 Cr. (Mar 2025) to 916.00 Cr., marking an increase of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 96.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 96.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Mar 2025) to 33.00 Cr., marking a decrease of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 788.00 Cr.. The value appears strong and on an upward trend. It has increased from 769.00 Cr. (Mar 2025) to 788.00 Cr., marking an increase of 19.00 Cr..
- For Total Assets, as of Sep 2025, the value is 916.00 Cr.. The value appears strong and on an upward trend. It has increased from 903.00 Cr. (Mar 2025) to 916.00 Cr., marking an increase of 13.00 Cr..
Notably, the Reserves (731.00 Cr.) exceed the Borrowings (7.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 44.00 | 36.00 | 62.00 | 67.00 | 60.00 | 77.00 | 71.00 | 82.00 | 58.00 | 54.00 | 30.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 105 | 114 | 83 | 68 | 74 | 79 | 104 | 89 | 99 | 87 | 71 | 99 |
| Inventory Days | 9 | |||||||||||
| Days Payable | 407 | |||||||||||
| Cash Conversion Cycle | 105 | 114 | 83 | 68 | 74 | -319 | 104 | 89 | 99 | 87 | 71 | 99 |
| Working Capital Days | 75 | 82 | 57 | 42 | 50 | 62 | 71 | 56 | 57 | 72 | 53 | 64 |
| ROCE % | 29% | 17% | 24% | 22% | 17% | 21% | 17% | 17% | 10% | 9% | 6% | 4% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| Diluted EPS (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.11 |
| Cash EPS (Rs.) | 5.45 | 8.72 | 13.47 | 14.87 | 21.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 240.71 | 227.77 | 221.21 | 197.37 | 181.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 240.71 | 227.77 | 221.21 | 197.37 | 181.30 |
| Revenue From Operations / Share (Rs.) | 291.71 | 415.67 | 413.41 | 338.01 | 320.09 |
| PBDIT / Share (Rs.) | 11.51 | 15.18 | 21.85 | 22.18 | 30.80 |
| PBIT / Share (Rs.) | 9.88 | 12.95 | 19.64 | 20.01 | 29.79 |
| PBT / Share (Rs.) | 8.60 | 12.41 | 18.92 | 19.11 | 28.91 |
| Net Profit / Share (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| NP After MI And SOA / Share (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| PBDIT Margin (%) | 3.94 | 3.65 | 5.28 | 6.56 | 9.62 |
| PBIT Margin (%) | 3.38 | 3.11 | 4.75 | 5.91 | 9.30 |
| PBT Margin (%) | 2.94 | 2.98 | 4.57 | 5.65 | 9.03 |
| Net Profit Margin (%) | 1.31 | 1.56 | 2.72 | 3.75 | 6.30 |
| NP After MI And SOA Margin (%) | 1.31 | 1.56 | 2.72 | 3.75 | 6.30 |
| Return on Networth / Equity (%) | 1.58 | 2.84 | 5.09 | 6.43 | 11.13 |
| Return on Capital Employeed (%) | 4.03 | 5.58 | 8.73 | 10.01 | 16.14 |
| Return On Assets (%) | 1.30 | 2.28 | 4.05 | 5.17 | 9.10 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 1.01 | 1.48 | 1.58 | 0.20 | 0.20 |
| Current Ratio (X) | 4.82 | 4.26 | 3.36 | 3.69 | 4.02 |
| Quick Ratio (X) | 4.76 | 4.21 | 3.30 | 3.67 | 3.99 |
| Inventory Turnover Ratio (X) | 109.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 12.76 | 28.21 | 30.01 | 24.69 | 34.91 |
| Interest Coverage Ratio (Post Tax) (X) | 5.66 | 13.05 | 16.47 | 15.12 | 23.89 |
| Enterprise Value (Cr.) | -195.88 | -48.38 | 147.35 | 204.15 | 3.24 |
| EV / Net Operating Revenue (X) | -0.21 | -0.03 | 0.11 | 0.19 | 0.00 |
| EV / EBITDA (X) | -5.53 | -1.03 | 2.19 | 2.99 | 0.03 |
| MarketCap / Net Operating Revenue (X) | 0.23 | 0.22 | 0.22 | 0.39 | 0.19 |
| Price / BV (X) | 0.28 | 0.41 | 0.41 | 0.68 | 0.34 |
| Price / Net Operating Revenue (X) | 0.23 | 0.22 | 0.22 | 0.39 | 0.19 |
| EarningsYield | 0.05 | 0.06 | 0.12 | 0.09 | 0.32 |
After reviewing the key financial ratios for Trigyn Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.45. This value is within the healthy range. It has decreased from 8.72 (Mar 24) to 5.45, marking a decrease of 3.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 291.71. It has decreased from 415.67 (Mar 24) to 291.71, marking a decrease of 123.96.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.51. This value is within the healthy range. It has decreased from 15.18 (Mar 24) to 11.51, marking a decrease of 3.67.
- For PBIT / Share (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has decreased from 12.95 (Mar 24) to 9.88, marking a decrease of 3.07.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 12.41 (Mar 24) to 8.60, marking a decrease of 3.81.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For PBDIT Margin (%), as of Mar 25, the value is 3.94. This value is below the healthy minimum of 10. It has increased from 3.65 (Mar 24) to 3.94, marking an increase of 0.29.
- For PBIT Margin (%), as of Mar 25, the value is 3.38. This value is below the healthy minimum of 10. It has increased from 3.11 (Mar 24) to 3.38, marking an increase of 0.27.
- For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has decreased from 2.98 (Mar 24) to 2.94, marking a decrease of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 5. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 8. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 15. It has decreased from 2.84 (Mar 24) to 1.58, marking a decrease of 1.26.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 5.58 (Mar 24) to 4.03, marking a decrease of 1.55.
- For Return On Assets (%), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 5. It has decreased from 2.28 (Mar 24) to 1.30, marking a decrease of 0.98.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.01. It has decreased from 1.48 (Mar 24) to 1.01, marking a decrease of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 4.82. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 24) to 4.82, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 25, the value is 4.76. This value exceeds the healthy maximum of 2. It has increased from 4.21 (Mar 24) to 4.76, marking an increase of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 109.49. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 109.49, marking an increase of 109.49.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 12.76. This value is within the healthy range. It has decreased from 28.21 (Mar 24) to 12.76, marking a decrease of 15.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.66. This value is within the healthy range. It has decreased from 13.05 (Mar 24) to 5.66, marking a decrease of 7.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is -195.88. It has decreased from -48.38 (Mar 24) to -195.88, marking a decrease of 147.50.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 1. It has decreased from -0.03 (Mar 24) to -0.21, marking a decrease of 0.18.
- For EV / EBITDA (X), as of Mar 25, the value is -5.53. This value is below the healthy minimum of 5. It has decreased from -1.03 (Mar 24) to -5.53, marking a decrease of 4.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
- For Price / BV (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.41 (Mar 24) to 0.28, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Trigyn Technologies Ltd:
- Net Profit Margin: 1.31%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.03% (Industry Average ROCE: 14.75%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.58% (Industry Average ROE: 19.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.66
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 42.6 (Industry average Stock P/E: 66.58)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.31%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | Unit 27, SDF 1, Mumbai Maharashtra 400096 | ro@trigyn.com http://www.trigyn.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Satyam Cherukuri | Chairman & Non-Exe.Director |
| Ms. P Bhavana Rao | Executive Director |
| Mr. R Ganapathi | Non Executive Director |
| Dr. P Raja Mohan Rao | Non Executive Director |
| Ms. Lakshmi Potluri | Independent Director |
| Mr. Ishwar Halalli | Independent Director |
| Mr. Syed Ahmed Sultan | Independent Director |
| Mr. Vijay Mallya | Independent Director |
FAQ
What is the intrinsic value of Trigyn Technologies Ltd?
Trigyn Technologies Ltd's intrinsic value (as of 11 December 2025) is 147.68 which is 112.80% higher the current market price of 69.40, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 214 Cr. market cap, FY2025-2026 high/low of 122/60.0, reserves of ₹731 Cr, and liabilities of 916 Cr.
What is the Market Cap of Trigyn Technologies Ltd?
The Market Cap of Trigyn Technologies Ltd is 214 Cr..
What is the current Stock Price of Trigyn Technologies Ltd as on 11 December 2025?
The current stock price of Trigyn Technologies Ltd as on 11 December 2025 is 69.4.
What is the High / Low of Trigyn Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Trigyn Technologies Ltd stocks is 122/60.0.
What is the Stock P/E of Trigyn Technologies Ltd?
The Stock P/E of Trigyn Technologies Ltd is 42.6.
What is the Book Value of Trigyn Technologies Ltd?
The Book Value of Trigyn Technologies Ltd is 247.
What is the Dividend Yield of Trigyn Technologies Ltd?
The Dividend Yield of Trigyn Technologies Ltd is 0.00 %.
What is the ROCE of Trigyn Technologies Ltd?
The ROCE of Trigyn Technologies Ltd is 4.17 %.
What is the ROE of Trigyn Technologies Ltd?
The ROE of Trigyn Technologies Ltd is 1.72 %.
What is the Face Value of Trigyn Technologies Ltd?
The Face Value of Trigyn Technologies Ltd is 10.0.